Press release

Royal DSM, a global science-based company in Nutrition, Health and Sustainable Living, will showcase AVANSYA™ Reb M at this year’s IFT. AVANSYA™ is DSM’s new brand for sustainably produced, non-artificial sweeteners that answer to the need for advanced, flexible sugar reduction in a wide range of foods and beverages. The first product in this range is AVANSYA Reb M (Rebaudioside M), a calorie-free steviol glycoside with a pure and clean taste, which is sustainably produced by fermentation.

Visitors to DSM’s booth at IFT can try AVANSYA Reb M in a sweetened yogurt application, where the new sweetener has enabled a 100% reduction in added sugar. AVANSYA Reb M, with its sugar-like sweetness, allows producers to achieve a zero-added-sugar product while maintaining a preferred taste profile in the application.

“With rates of overweight and obesity on the rise globally, the food industry is looking for ways to create healthier versions of the foods and beverages consumers love,” says Luiz Leite, Director of DSM’s Sugar Reduction Platform. “We believe that better sweeteners - which taste better, are non-artificial, and offer advanced sugar reduction opportunities - will be an important part of the solution. We are proud to introduce AVANSYA Reb M at IFT this year and ultimately, to contribute to healthy, sustainable food and beverage products for people around the world.”

AVANSYA Reb M is a non-artificial sweetener that is identical to Reb M found in the Stevia plant. It is produced by fermentation, a natural, cost-efficient process that is sustainable and offers consistent, scalable supply. DSM’s novel and patented technology for purifying steviol glycosides from fermentation is completely water-based and solvent-free, which benefits sustainability.

DSM’s AVANSYA Reb M is GRAS in the US, and registered for use in Mexico with COFEPRIS. DSM expects to provide commercial quantities of AVANSYA Reb M to customers in the US and Mexico in the second half of the year, and thereafter in the rest of the world pursuant to regulatory approvals and in line with the company’s production scale-up plan.